Form 4: Unicycive Therapeutics CEO Acquires Stock Options
SEC Form 4
Shalabh K. Gupta, CEO of Unicycive Therapeutics, reports acquisition of stock options.
Summary
- On April 15, 2024, Shalabh K. Gupta, CEO of Unicycive Therapeutics, acquired 1,319,583 stock options with an exercise price of $1.14.
- Following the transaction, Gupta directly owns 6,206,637 shares of common stock.
- The stock options vest over time, with 329,896 vesting on the first anniversary of the grant date and the remainder vesting monthly thereafter.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports an insider transaction, which can be interpreted as either positive (confidence) or neutral (routine).
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring these transactions can provide insights into management's sentiment about the company's prospects.
Stakeholder Impact
- The acquisition of stock options by the CEO may have a slight positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/15/2024 | Date of stock options transaction |
| 04/15/2034 | Expiration date of stock options |
| 04/17/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.